A decade-long legal saga surrounding one of Wall Street’s most infamous insider trading cases has finally closed a major chapter.
A federal judge has officially awarded Pfizer (PFE) $29 million to resolve a dispute with the SEC stemming from the 2013 insider trading fallout at Steven A. Cohen’s former hedge fund, SAC Capital Management.
📜 THE LEGAL BREAKDOWN:
- The Backstory: The case originates from former SAC employee Mathew Martoma, who was jailed for trading on insider tips regarding a 2008 Alzheimer’s drug trial involving Wyeth (which Pfizer acquired in 2009).
- The Dispute: After victim payouts, $75.2 million remained from SAC’s massive $601.8 million SEC settlement. A judge initially ruled the leftover cash should go to the U.S. Treasury, arguing Wyeth wasn’t a direct “victim.”
- The Reversal: Pfizer aggressively appealed, arguing the neurologist who leaked the trial data owed Wyeth a strict fiduciary duty.
- The Compromise: To avoid further litigation, Pfizer agreed to drop the appeal in exchange for a $29 million cut, leaving the U.S. Treasury with the remaining $46.2 million.
💡 ANALYST TAKEAWAY: This settlement is a stark reminder of the incredibly long-tail financial and legal consequences of corporate espionage and insider trading. For corporate legal teams, Pfizer’s aggressive (and successful) appeal proves that relentlessly pursuing restitution for inherited fiduciary breaches during M&A can literally pay off—even a decade after the original crime.
👇 Corporate Law & Compliance Professionals: Does a $29M payout justify years of complex federal appeals, or is this more about setting a strict legal precedent regarding fiduciary duty in clinical trials?